This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ran, M. Articles by Witz, I. P. Search for Related Content PubMed PubMed Citation Articles by Ran, M. Articles by Witz, I. P.

In Vivo Acquisition of FcRII Expression on Polyoma Virus-transformed Cells Derived from Tumors of Long Latency¹

Department of Microbiology and the Moise and Frida Eskenasy Institute for Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel [M. R., B. K., N. K., E. H., Y. B-F, E. A., I. P. W.], and Laboratoire d'Immunologie Celluaire et Clinique, INSERM U. 255, Institute Curie, Paris, France [J-L. T., J. E., W. H. F.]

BALB/c3T3 cells transformed in vitro with polyoma virus were cloned and passaged once in syngeneic mice. Resulting tumors from each clone were explanted and recultured. Expression of receptor for Fc of IgG (FcRII) in the original in vitro maintained clones and in cells derived from tumors elicited by the respective cells was measured at the protein level as well as at the mRNA level. Clones were assayed in pairs. The ancestor in vitro maintained clones [designated cultured cells (C)] were compared with cells derived from the same clones after a single passage in vivo followed by explanation and reculturing [designated cultured-tumor-cultured cells (CTC)]. C cells of any of the tested clones did not express FcRII. On the other hand, certain CTC cells were positive. The FcRII-positive cells were derived from tumors appearing after a long precancer latency period (>140 days). CTC cells derived from tumors that appeared after shorter latency periods (<80 days) were FcRII negative. These results were obtained both by using radioimmunoassay and monoclonal antibodies against mouse FcRII as well as by Northern blot analysis using the FcRII complementary DNA probe. The involvement of macrophages as the FcRII-expressing cells in CTC cells was excluded.

FcRII expression was down-regulated in CTC cells as a function of time following their explantation into culture. FcRII expression could be up-regulated in these cells and induced on C cells by maintaining the cultured cells in the presence of normal mouse serum or recombinant interferon. We also tested the expression of FcRII on CTC cells following their inoculation into syngeneic mice for a second time (CTCx2 cells). The results showed a positive correlation between FcRII expression in the inoculated ancestor CTC cells and on the CTCx2 cell progeny.

¹ This work has been supported by the Israel Cancer Association, Tel Aviv; the National Council for Research and Development, Jerusalem; Association pour la Recherche sur le Cancer, Paris; Concern Foundation, Los Angeles; The Fainbarg Family Fund, Orange County; and the Mary A. Pikovski Fund, Jerusalem. Yehudit Berko-Flint is a fellow of the Israel Cancer Research Fund and Isaac P. Witz is the incumbent of the David Furman Chair in Immunobiology of Cancer.

Received 5/30/90. Accepted 10/26/90.